BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5

BioRestorative Therapies, Inc.

Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.
Company will host a webcast conference call with slide presentation on Feb 5, 2024 at 8:30 a.m. ET to review the poster.
No specific efficacy or safety results were disclosed in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.